摘要
目的:观察诺和龙的降糖效果及在控制血糖的情况下,发生低血糖的情况。方法:将124例2型糖尿病患者随机分成3组,A组单独采用诺和龙治疗,B组与二甲双胍联合治疗,C组与α糖苷酶抑制剂联合治疗。观察各组治疗对2型糖尿病患者血糖控制的影响,疗程共12周。结果:单用诺和龙组,空腹血糖平均下降23.5%,餐后2h血糖平均下降32.6%,与α糖苷酶抑制剂联合治疗组空腹血糖平均下降15.7%,餐后2h血糖平均下降29.8%,与二甲双胍联合治疗组空腹血糖平均下降21.8%,餐后2h血糖平均下降32.5%。结论:诺和龙单独用药,还是联合用药,均可显著降低2型糖尿病患者的空腹血糖及餐后血糖。且未见低血糖和其他严重不良反应。
Objective： To investigate the effects of repaglinide on type 2 diabetes and side effects of hypoglycemia. Methods： One hundred and twenty-four patients with type 2 diabetes were divided randomly into 3 groups, patients in group A were treated with repagli metformin, and patients in group C were treated with nide, patients in group B were treated with repaglinide and repaglinide and α glucosidase inhibitor; the therapy course was 12 weeks; effect of blood glucose control and side effects were observed and compared. Results： Avarage fasting blood glucose 2 hours postprandial blood glucose decrease in patients of group A, B and C were 23.5%, 32. 6% and 21.8%, 32.5 % and 15.7%, 29.8 % respectively. Conclusion： Repaglinide alone or combined with other medication can significantly lower fasting blood glucose and postprandial blood glucose of patients with type 2 diabetes, and no hypoglycemia and other serious adverse reactions occure.
出处
《海南医学院学报》
CAS
2009年第9期1157-1159,共3页
Journal of Hainan Medical University
基金
东莞市科研立项课题(2007105150116)
关键词
诺和龙
非胰岛素依赖型糖尿病
血糖
Repaglinide
Non-insulin-dependent diabetes
Blood glucose
